{
  "docId": "019de074-a4f4-74e1-8870-171c8951fea8",
  "docSlug": "e0247ed9fbf6e59fd6aeeea6f3eacc2d",
  "documentTitle": "23andMe | Investor Presentation Deck | 57 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 46,
  "pageCount": 57,
  "prevPage": 45,
  "nextPage": 47,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide outlines the mechanism of action, clinical rationale, and upcoming Phase 2a study design for the drug candidate.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-a4f4-74e1-8870-171c8951fea8/46",
  "deckHref": "/decks/019de074-a4f4-74e1-8870-171c8951fea8",
  "deckJsonHref": "/decks/019de074-a4f4-74e1-8870-171c8951fea8.json",
  "deckAnchorHref": "/decks/019de074-a4f4-74e1-8870-171c8951fea8#slide-46",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "1. Data presented in poster at 2022 American Association for Cancer Research (AACR) annual meeting.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "369e56af-fa23-474a-a76d-509a6b1b3507",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "CD200R1 is an immune checkpoint with a strong I/O signature in three components of the pathway. 23ME-00610 is a high-affinity, first-in-class, anti-CD200R1 antibody with immune-activating properties, including: Prevention of CD200-mediated suppression of chronically stimulated T cells; Enhancement of cytokine secretion from peripheral blood mononuclear cells (PBMCs) isolated from cancer patients; Augmentation of PBMC-mediated tumor cell killing. CD200R1 expression was observed on tumor infiltrating lymphocytes from The Cancer Genome Atlas, suggesting that this pathway contributes to an immunosuppressive tumor microenvironment. CD200R1 was also expressed in immune checkpoint inhibitor non-responders, indicating that inhibition of the CD200R1 immune checkpoint has the potential to address resistance to anti-PD-1 and anti-CTLA4 therapies. Phase 2a portion of the study study will evaluate five tumor indication-specific expansion cohorts and a cohort of adolescents with locally advanced unresectable, or metastatic solid malignancies.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "610cfe1d-403d-4e9f-806a-4507ddfa78d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "23ME'610 Targeting CD200R1: A Genetically-Validated Approach to Anti-Cancer Therapy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e54e13b1-e03b-40a8-a1fe-90391a2f4049",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Thesis archetype",
      "slug": "thesis-archetype",
      "agent": null,
      "layer": "slide",
      "matchId": "9e69eeca-2186-455f-b75f-6045d50b299e",
      "evidence": "CD200R1 is an immune checkpoint with a strong I/O signature in three components of the pathway.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 48,
      "from": 36,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "25bf5fec-1759-4ae6-8d05-5ad619b628ea",
      "evidence": "The deck presents 23andMe's research and development pipeline and its immuno-oncology programs",
      "position": 2,
      "objective": "What are the opportunities for 23andMe in therapeutics development?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}